Evidence map›Paper›PMID 18758473›Full record

ReviewNature reviews. Drug discovery2008

Adenosine receptors: therapeutic aspects for inflammatory and immune diseases.

György Haskó, Joel Linden, Bruce Cronstein, Pál Pacher

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Nature reviews. Drug discovery, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03516903 (Effect of Methotrexate Carried by a Lipid Nanoemulsion on Left Ventricular Remodeling After ST-elevation Myocardial Infarction), which is not on this map. Cited by 651 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
651citing papers in PubMed, 2 pooled it
41.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03516903 phase2 / phase3terminatednot on this mapstarted 2018, after this paper: background citation

Effect of Methotrexate Carried by a Lipid Nanoemulsion on Left Ventricular Remodeling After ST-elevation Myocardial Infarction

TypeinterventionalSponsorUniversity of Sao PauloRan2018 to 2020Enrolled35ConditionsMyocardial Infarction, Anterior Wall, Myocardial Remodeling, VentricularArmsMethotrexate, Placebo, Folic Acid
3 · Its place in the literature

Who cites it

651 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,211 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. From danger to resolution: targeting purinergic signaling in CNS diseases.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Inflammatory Response of Presbyopes Neophyte Contact Lens Wearers during 6 Months of Multifocal Lens Wear.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026
    Article
  20. Article

591 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

György HaskóDepartment of Surgery, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, 185 South Orange Avenue, Newark, New Jersey 07103, USA. haskoge@umdnj.edu
Joel Linden
Bruce Cronstein
Pál Pacher
National Institute on Alcohol Abuse and Alcoholism · USNew York University · USRutgers, The State University of New Jersey · USUniversity of Virginia · US

Funding

Purinergic signaling in trauma and sepsisR01GM066189 · NIGMS · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI HASKO, GEORGE · 2002 to 2020
$4.7M
Mechanism of oxidative/nitrosative stress and inflammation-induced tissue injuryZ01AA000375 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI PACHER, PAL · 2006 to 2008
$1.3M
Adenosine in trauma and sepsisR56GM066189 · NIGMS · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI HASKO, GYORGY · 2007 to 2007
$272k
Intramural NIH HHS Z01 AA000375Intramural NIH HHS Z99 AA999999NIGMS NIH HHS R01 GM066189NIGMS NIH HHS R01 GM66189NIGMS NIH HHS R56 GM066189
6 · The paper itself

Abstract

Adenosine is a key endogenous molecule that regulates tissue function by activating four G-protein-coupled adenosine receptors: A1, A2A, A2B and A3. Cells of the immune system express these receptors and are responsive to the modulatory effects of adenosine in an inflammatory environment. Animal models of asthma, ischaemia, arthritis, sepsis, inflammatory bowel disease and wound healing have helped to elucidate the regulatory roles of the various adenosine receptors in dictating the development and progression of disease. This recent heightened awareness of the role of adenosine in the control of immune and inflammatory systems has generated excitement regarding the potential use of adenosine-receptor-based therapies in the treatment of infection, autoimmunity, ischaemia and degenerative diseases.

Indexed as

AnimalsAutoimmune DiseasesClinical Trials as TopicDisease Models, AnimalDisease ProgressionHumansInflammationIschemiaReceptors, Purinergic P1Signal TransductionReceptors, Purinergic P1

Identifiers

PMID18758473
PMCPMC2568887
OpenAlexW2003483275

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.